|
Status |
Public on Nov 01, 2021 |
Title |
A799 |
Sample type |
RNA |
|
|
Source name |
KPfC pancreatic tumor
|
Organism |
Mus musculus |
Characteristics |
tissue: KPfC orthotopic pancreatic tumor treatment: Vehicle
|
Treatment protocol |
For KPfC endpoint study, therapy was initiated at day 10 post tumor cell injection. Treatments consist of 8 groups: vehicle; TP-0903, 25 mg/kg, daily, oral gavage; gemcitabine, 25 mg/kg, ip, 3x/week; anti-PD1 antibody (clone: RMP14-1), 5 mg/kg, ip, twice per week; TP-0903+gemcitabine; TP-0903+anti-PD1; TP-0903+gemcitabine+anti-PD1; gemcitabine+anti-PD1. All mice were sacrificed on Day 35.
|
Growth protocol |
0.5 × 10^6 KPfC BMF-A3 cells were implanted orthotopically into WT C57BL/6 mice. Ultrasound was done on a cohort of animals to confirm tumor burden before therapy was initiated.
|
Extracted molecule |
total RNA |
Extraction protocol |
KPfC tumor tissues from orthotopic endpoint experiment were lysed in RLT lysis buffer and purified according to the manufacturer’s instructions (QIAGEN). Quality control was performed with Agilent Bioanalyser.
|
Label |
NanoString nCounter probes
|
Label protocol |
NA
|
|
|
Hybridization protocol |
Total RNA from each sample was hybridized to the CodeSet nCounter PanCancer Immune Profiling Panel, Mouse.
|
Scan protocol |
The scanning was processed on the NanoString Technologies nCounter Sprint Profiler.
|
Description |
A799
|
Data processing |
We used the nSolver Analysis Software 4.0 (NanoString Technologies). Samples were normalized based on the geometric means of the supplied positive controls and the panel of housekeeping genes.
|
|
|
Submission date |
Sep 30, 2021 |
Last update date |
Nov 02, 2021 |
Contact name |
Yuqing Zhang |
E-mail(s) |
yuqing.zhang@utsouthwestern.edu
|
Organization name |
UTSouthwestern Medical Center
|
Department |
Surgery
|
Lab |
Rolf Brekken
|
Street address |
6000 Harry Hines Blvd
|
City |
Dallas |
State/province |
TX |
ZIP/Postal code |
75390 |
Country |
USA |
|
|
Platform ID |
GPL30298 |
Series (1) |
GSE185110 |
Transcriptomic analysis of orthotopic pancreatic tumors treated by Axl inhibitor TP-0903 or combination with chemo/immunotherapy using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [mouse] |
|